These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22967422)

  • 1. [Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
    Bao L; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):573. PubMed ID: 22967422
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose melphalan in myelodysplastic syndromes: an effective treatment for elderly RAEB-I or II patients?
    Xiao Z; Liu L; Xu Z; Qin T; Zhang Y; Zhang T
    Leuk Lymphoma; 2010 Mar; 51(3):549-51. PubMed ID: 20038270
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
    Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
    Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
    Möller I; Blum S; Gattermann N; Haas R; Habersang K; Germing U; Kuendgen A
    Ann Hematol; 2009 Nov; 88(11):1141-4. PubMed ID: 19290525
    [No Abstract]   [Full Text] [Related]  

  • 10. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
    Wijermans PW; Krulder JW; Huijgens PC; Neve P
    Leukemia; 1997 Jan; 11(1):1-5. PubMed ID: 9001409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of myelodysplastic syndrome with alfacalcidol].
    Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901
    [No Abstract]   [Full Text] [Related]  

  • 13. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP
    Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
    Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
    Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
    Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
    Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
    [No Abstract]   [Full Text] [Related]  

  • 17. A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment.
    Fujita Y; Nakazato T; Ito C; Masuda K; Osada Y; Aisa Y; Mori T
    Ann Hematol; 2018 Oct; 97(10):2009-2010. PubMed ID: 29713749
    [No Abstract]   [Full Text] [Related]  

  • 18. Spontaneous splenic rupture in myelodysplastic syndrome.
    Raafat A; Mills MJ; Traub NE; Townend DM; Hoffbrand AV
    Eur J Haematol; 1989 Apr; 42(4):410-1. PubMed ID: 2721665
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.
    Xu Z; Shier L; Sabloff M; McCurdy A; Sheppard D; Bredeson C
    Br J Haematol; 2014 Oct; 167(2):147. PubMed ID: 25040664
    [No Abstract]   [Full Text] [Related]  

  • 20. Myelodysplastic syndrome with erythroid hypoplasia: a rare and distinct clincopathological entity--a report of two cases.
    Kumar V; Dash S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):36-7. PubMed ID: 16758786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.